Leukemia Research
Volume 34, Issue 4 , Pages 418-419 , April 2010

Pediatric acute lymphoblastic leukemia: There is no TEL-ing what wonders lie ahead

Received 7 October 2009

References 

  1. Pui C-H, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia with cranial irradiation. N Eng J Med. 2009;360:2730–2741
  2. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myelogenous leukemia. Leukemia. 2009;23:1054–1061
  3. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24
  4. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffé M, Jonveaux P, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995;86:4263–4269
  5. Wiemels JL, Cazziniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499–1503
  6. Pine SR, Wiemels JL, Jayabose S, Sandoval C. TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia. Leuk Res. 2003;27:155–164
  7. Wiemels JL, Hoffman J, Kang M, Selzer R, Green R, Zhou M, et al. Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally. Cancer Res. 2008;68:9935–9944
  8. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985–1989
  9. Gardemer V, Aubry M, Roussel M, Gio A-G, DeTayrac M, Vallee A, et al. CD9 expression can be used to predict childhood TEL/AML 1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart. Leuk Res. 2010;34:430–437
  10. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133–143
  11. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951–2959
  12. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–908
  13. Rousselot P, Huget F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60

PII: S0145-2126(09)00502-5

doi: 10.1016/j.leukres.2009.10.009

Leukemia Research
Volume 34, Issue 4 , Pages 418-419 , April 2010

Article Tools